End Stage Renal Disease clinical trials

Explore recruiting end stage renal disease clinical trials.

Recruiting end stage renal disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

End Stage Renal Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized Parallel-group, Placebo-controlled, Double-blind, Eventdriven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis

Germany, Czechia, Greece, Italy, Portugal, Bulgaria +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, open, prospective, randomized, parallel-group, 12-month trial of REduced immunosuppression for oLdEr AdultS kidnEy transplant recipients: the RELEASE study.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure – Chronic Kidney Disease (SAFE LAAC CKD). Comparative Health Effectiveness Ancillary Study – PILOT

Poland

Therapeutic use (Phase IV) EU CTIS Study details

Chronic anticoagulation in end-stage renal disease patients: pharmacocinetics and pharmacodynamic of a reduced dose regimen of rivaroxaban (CARD-AXA)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial

France

Phase III and phase IV (Integrated) EU CTIS Study details

End Stage Renal Disease trials by city

End Stage Renal Disease in Toronto End Stage Renal Disease in Vancouver End Stage Renal Disease in Montreal End Stage Renal Disease in Calgary End Stage Renal Disease in Edmonton End Stage Renal Disease in Ottawa End Stage Renal Disease in Winnipeg End Stage Renal Disease in Quebec City End Stage Renal Disease in Hamilton End Stage Renal Disease in Kitchener End Stage Renal Disease in London End Stage Renal Disease in Halifax End Stage Renal Disease in New York End Stage Renal Disease in Los Angeles End Stage Renal Disease in Chicago End Stage Renal Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease